At a recent press conference, Pfizer executives shared a few key updates related to Inflectra’s uptake and the ongoing efforts to work with commercial payers. These updates not only shed more light on Inflectra’s market journey, but also reassured me that progress is being made — even though it’s not regularly broadcast in headlines.
This year, The Biosimilar Medicines Group, a Medicines for Europe sector group, will host its 16th annual conference. While I will be unable to attend the event once again this year, I was thrilled to have the opportunity to chat with Carol Lynch, chair of the Biosimilar Medicines Group for Medicines for Europe, about the upcoming conference.
In the first of this two-part article, McKesson experts share insights on two biosimilar barriers they’ve noticed in community clinics and highlight their takeaways from infliximab’s and filgrastim’s experiences tackling these barriers.
This review sought to answer two questions which have been plaguing the biosimilar industry since day one: will biosimilar switching have any impact on safety, and will biosimilars be the harbingers of increased immunogenicity? And it has provided us with far more than just answers to these questions.
A prediction that a failure of the U.S. biosimilars market could lead to the end of the global biosimilars market begs the question of how we evaluate progress, as well as how such a prediction could be avoided.
What could a country like the U.S. and big payers like the Aetna’s, UnitedHealthcare’s, or even the PBMs like CVS learn from what other countries have done to garner savings for their healthcare systems and potentially reduce costs for patients?
In addition to understanding what influences employers’ health plan decision-making, it’s important to note employers' growing demands for greater pricing transparency and the complexity posed by the lack of an integrated benefits system.
It’s been hard to miss some of the good buzz coming out of the U.K. as the acceptance and adoption of biosimilars continues to be one of the strongest across Europe, and the NHS published its highly anticipated framework to help guide the use of biosimilars. But how the new framework will shape the U.K. biosimilar market is only just being seen.
Many have predicted payers will be the stakeholders to carry biosimilars across the finish line. But as the past few years will attest, this has not turned out to be the case, and this realization leaves the biosimilar industry asking an important, somewhat nerve-wracking question:
The first of this three-part article touches on the current biosimilar-related developments ongoing in the U.K., as well as what the new chair of the British Biosimilars Association (BBA) is keeping her eyes on, both in the U.K. and globally.
|
|
|
|
|
|
|
|
|